Predictive oncology inc. to attend bio digital, the world's largest biotech partnering experience

Minneapolis, june 02, 2021 (globe newswire) -- predictive oncology (nasdaq: poai), a knowledge-driven company focused on applying artificial intelligence (“ai”) to personalized medicine and drug discovery, announced today that its three wholly owned subsidiaries, helomics, tumorgenesis and soluble biotech, will be attending bio digital, a key international biotech partnering event held virtually on june 10-11 & 14-18, 2021.
POAI Ratings Summary
POAI Quant Ranking